7/106 sources · 4 publishersUpdated Nov 12, 13:58 UTC
Twist Bioscience reports Q4 earnings beat and raises FY2027 revenue outlook
Twist Bioscience posted fourth‑quarter revenue of $126.6 million and a GAAP loss of $0.32 per share, both beating analyst estimates. The company announced full‑year 2026 revenue of $459.4 million, up 22% year‑over‑year, and guided FY2027 revenue to $550 million‑$560 million. Management also said adjusted EBITDA turned positive in Q4. The results were released on 12 Nov 2026.
Why it matters
The earnings beat and higher guidance suggest accelerating growth, but the pre‑market share decline indicates market skepticism about profitability. Investors will watch whether the positive adjusted EBITDA translates into sustained cash flow.
Key facts
- 1Q4 revenue was $126.6 million. seekingalpha.com
- 2Q4 GAAP loss was $0.32 per share. seekingalpha.com
- 3Full‑year 2026 revenue was $459.4 million, up 22% YoY. tradingview.com
- 4Adjusted EBITDA was $2.2 million in Q4. tradingview.com
- 5FY2027 revenue guidance is $550 million‑$560 million. tradingview.com
- 6Full‑year 2026 revenue guidance from earlier guidance was $456 million‑$457 million. investing.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.